Updates are available Correction dated 2020-12-15
Click to view Correction: https://doi.org/10.1038/s41433-020-01351-7
-
Authors
Sharma, Ashish http://orcid.org/0000-0002-8550-9791
Kumar, Nilesh http://orcid.org/0000-0002-7439-2081
Parachuri, Nikulaa
Sadda, Srinivas R.
Corradetti, Giulia http://orcid.org/0000-0001-9213-5575
Heier, Jeffrey
Chin, Adam T. http://orcid.org/0000-0002-8539-754X
Boyer, David
Dayani, Pouya
Arepalli, Sruthi
Kaiser, Peter http://orcid.org/0000-0001-5126-045X
- License Information
-
More Information
Article History
Received: 19 June 2020
Revised: 15 July 2020
Accepted: 16 July 2020
First Online: 24 July 2020
Change Date: 15 December 2020
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1038/s41433-020-01351-7
Compliance with ethical standards
:
: AS: CONSULTANT: for Novartis, Allergan, Bayer and Intas; SRS reports and Consultant: Amgen, Allergan, Novartis, Regeneron, Roche/Genentech, 4DMT. Merck, Optos, Centervue, Heidelberg; Research Instruments: Topcon, Nidek, Carl Zeiss Meditec, Optos, Centervue, Heidelberg. JH’s disclosures are as follows: Consulting: 4DMT, Adverum, Aerie, Aerpio, Aldeyra, Allegro, Alzheon, Annexon, Apellis, Asclepix, Beaver-Visitec, Galimedix, Genentech, Gyroscope, iRenix, jCyte, Kala, Kanghong, NGM, Notal Vision, Novartis, Ocugenix, Oculis, Ocunexus, Ocular Therapeutix, Palatin, Pfizer, Regeneron, Regenxbio, Santen, Scifluor, Shire, Stealth, Tyrogenex, Voyant; Research: Aerie, Aerpio, Apellis, Genentech, Graybug, Gyroscope, Hemera, Janssen R&D, KalVista, Kanghong, Novartis, Ophthotech, Optovue, Regeneron, Regenxbio, Stealth; Equity: Adverum, Aldeyra, Allegro, Aviceda, Digital Surgery Systems, jCyte, Ocular Therapeutix; DB reports and Consultant: Genentech, Allergan, Roche, Regeneron, Bayer, Novartis. PK reports and Consultant: Allergan, Bayer, Novartis, Kanghong, Kodiak, RegenexBio, Regeneron. The other authors declare that they have no conflict of interest.
